CorrespondenceBrain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients
References (15)
- et al.
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS
Psychiatry Res
(2011) - et al.
Long-term repetitive transcranial magnetic stimulation increases the expression of brain-derived neurotrophic factor and cholecystokinin mRNA, but not neuropeptide tyrosine mRNA in specific areas of rat brain
Neuropsychopharmacology
(2000) - et al.
Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders
Neuropharmacology
(2012) - et al.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression
Arch Gen Psychiatry
(2006) - et al.
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression
Arch Gen Psychiatry
(2010) - et al.
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists
Science
(2010) - et al.
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Nature
(2011)
There are more references available in the full text version of this article.
Cited by (177)
Promising new pharmacological targets for depression: The search for efficacy
2023, Drug Discovery TodayBridging rapid and sustained antidepressant effects of ketamine
2023, Trends in Molecular MedicineRole of the mesolimbic dopamine pathway in the antidepressant effects of ketamine
2023, NeuropharmacologyRole of group II metabotropic glutamate receptors in ketamine's antidepressant actions
2023, Pharmacology Biochemistry and BehaviorGenetics of antidepressant response and treatment-resistant depression
2023, Progress in Brain Research
Authors GL and NL contributed equally to this work.
Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.